LLY

1,056.77

+2.85%↑

JNJ

214.01

+1.22%↑

ABBV

226.58

+1.4%↑

UNH

339.57

-0.53%↓

AZN

91.08

+1.44%↑

LLY

1,056.77

+2.85%↑

JNJ

214.01

+1.22%↑

ABBV

226.58

+1.4%↑

UNH

339.57

-0.53%↓

AZN

91.08

+1.44%↑

LLY

1,056.77

+2.85%↑

JNJ

214.01

+1.22%↑

ABBV

226.58

+1.4%↑

UNH

339.57

-0.53%↓

AZN

91.08

+1.44%↑

LLY

1,056.77

+2.85%↑

JNJ

214.01

+1.22%↑

ABBV

226.58

+1.4%↑

UNH

339.57

-0.53%↓

AZN

91.08

+1.44%↑

LLY

1,056.77

+2.85%↑

JNJ

214.01

+1.22%↑

ABBV

226.58

+1.4%↑

UNH

339.57

-0.53%↓

AZN

91.08

+1.44%↑

Kodu・Aktsiate loetelu・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Avatud

8.14 -0.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.91

Max

8.24

Põhinäitajad
By Trading Economics
Sissetulek	4.2M -23M
Kasumimarginaal	-2,027.003
Töötajad	83
EBITDA	6.6M -23M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+67.4% upside

Turustatistika
By TradingEconomics
Turukapital	41M 628M
Eelmine avamishind	8.75
Eelmine sulgemishind	8.14

Ventyx Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2025, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13. dets 2025, 00:04 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14. dets 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14. dets 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14. dets 2025, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101M Copper Miner Alta

14. dets 2025, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Acquire Remaining 64% of Alta Copper

14. dets 2025, 17:00 UTC

Tulu

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14. dets 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13. dets 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 08:00 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 07:00 UTC

Omandamised, ülevõtmised, äriostud

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. dets 2025, 00:24 UTC

Omandamised, ülevõtmised, äriostud

Want a Piece Of SpaceX? -- Barrons.com

12. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. dets 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. dets 2025, 22:32 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 20:45 UTC

Tulu

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. dets 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. dets 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. dets 2025, 19:23 UTC

Tulu

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. dets 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. dets 2025, 18:33 UTC

Omandamised, ülevõtmised, äriostud

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. dets 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. dets 2025, 17:49 UTC

Tulu

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. dets 2025, 17:34 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Võrdlus sarnastega

Hinnamuutus

Ventyx Biosciences Inc Prognoos

Hinnasiht

By TipRanks

67.4% tõus

12 kuu keskmine prognoos

Keskmine 13.71 USD 67.4%

Kõrge 21 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ventyx Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ventyx Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.